Rockefeller Capital Management
MDGL icon

Rockefeller Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Rockefeller Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6M Sell
29,015
-4,834
-14% -$2.48M 0.02% 567
2026
Q1 		$17.7M Buy
33,849
+14,188
+72% +$6.78M 0.03% 474
2025
Q4 		$11.4M Buy
19,661
+1,210
+7% +$618K 0.02% 623
2025
Q3 		$8.46M Buy
18,451
+503
+3% +$188K 0.02% 674
2025
Q2 		$5.43M Buy
17,948
+339
+2% +$101K 0.01% 764
2025
Q1 		$5.83M Sell
17,609
-601
-3% -$197K 0.01% 697
2024
Q4 		$5.62M Buy
18,210
+122
+0.7% +$34.3K 0.01% 692
2024
Q3 		$3.84M Sell
18,088
-1,000
-5% -$256K 0.01% 788
2024
Q2 		$5.35M Sell
19,088
-16,073
-46% -$3.83M 0.02% 668
2024
Q1 		$9.39M Buy
35,161
+2,121
+6% +$500K 0.03% 522
2023
Q4 		$7.64M Buy
33,040
+14,926
+82% +$2.61M 0.03% 534
2023
Q3 		$2.65M Buy
18,114
+6,289
+53% +$1.18M 0.01% 743
2023
Q2 		$2.73M Buy
11,825
+1,735
+17% +$470K 0.01% 746
2023
Q1 		$2.44M Buy
+10,090
New +$2.75M 0.01% 748

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Rockefeller Capital Management's MDGL Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 14% in Q2 2026, selling an estimated $2.48M and leaving 29,015 shares worth $15.6M. The position accounts for 0.02% of the portfolio, ranked #567.

Rockefeller Capital Management first reported a position in MDGL in Q1 2023 and has held it in 14 quarters since. The position peaked at $17.7M in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Rockefeller Capital Management held 29,015 shares of Madrigal Pharmaceuticals worth $15.6M as of Q2 2026.
  • Rockefeller Capital Management sold 4,834 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2.48M.
  • Madrigal Pharmaceuticals made up 0.02% of Rockefeller Capital Management's portfolio in Q2 2026, its #567 holding.
  • Rockefeller Capital Management first reported a position in Madrigal Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Rockefeller Capital Management's Madrigal Pharmaceuticals position peaked at $17.7M in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.